Insider buying last 90 days
No open-market insider purchases were filed for SVRA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SVRA insider filing, plotted on the chart in Gekko.Open SVRA in Gekko
NASDAQ: SVRA
Savara (SVRA) Stock Analysis & Forecast
Oct 12 close
$4.84−0.08 (−1.6%)
Gekko Brief
AI summaryOct 12 closeThis week JPMorgan initiated coverage on Savara with an Overweight rating and a $12 price target, a view the firm repeated across several notes, framing its outlook around the potential FDA decision on Molbreevi (molgramostim) expected November 22. Savara also announced an encore oral presentation and poster at CHEST 2026 covering IMPALA and IMPALA-2 trial data in autoimmune pulmonary alveolar proteinosis. Separately, JPMorgan's coverage noted Savara's Q2 2026 loss of $0.16 per share versus an expected $0.14.
SVRA closed at $4.84, down 1.6%, sitting below both its 50-day average of $5.31 and 200-day average of $5.48, with the 50-day below the 200-day. The stock is down 8.7% over one month, 14.9% over three months, and 18.2% over six months, though still up 41.5% over the past year. The GekkoIndex reads 62.9, in the Accumulation zone, down 5.4 points over five days. Price sits 34% below the Gekko Fair Value of $7.33.
The next earnings date falls on 11 November 2026, 29 days out and outside a typical 20-trading-day holding window; the last report showed an EPS miss with a 0.5% reaction. No insider, Congress, or unusual options activity appears in the recent windows, and no billionaire holders are recorded. Seasonality over five years shows a 0.3% average return across the next 20 trading days, positive in 3 of those years. Analyst consensus across 6 firms stands at Buy, with a consensus target of $11.06 implying 128.5% upside. Worth noting is the approaching FDA decision date as the next major catalyst.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Savara price vs fair value
Close $4.84200-day averageGekko Fair Value $7.33
Savara quick facts
- Market cap
- $991.8M
- P/E ratio
- —
- Forward P/E
- 0.4
- EPS, TTM
- −$0.58
- Revenue, TTM
- $1K
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.20
- Volume
- 1.31M avg 2.37M
- 1-year return
- +41.5%
- Typical daily move
- ±5.5%
- Typical 20-day move
- ±9.8%
- 50-day average
- $5.31
- 200-day average
- $5.48
- Next earnings
- Nov 11
- Shares outstanding
- 205.5M
Savara swing-trade checklist
Savara scores 4 supportive, 0 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed1 headwind
- Trendheadwind
Below 50 and 200-day
Close $4.84 is below the 50-day ($5.31) and 200-day ($5.48) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
62.9, Accumulation
Reading 62.9 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
34.0% below
Price is 34% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Nov 11, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.3% on average
From this point in the calendar, the next 20 trading days averaged +0.3% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Savara stock chart and price history
Savara closed at $4.84 on Oct 12, 2026, +41.5% over the past year, inside a 52-week range of $3.35 to $7.01.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −8.7%
- 3 months
- −14.9%
- 6 months
- −18.2%
- 1 year
- +41.5%
The full SVRA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SVRA in Gekko
Follow Savara through every session
Put SVRA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SVRA in GekkoFree for 7 days. No credit card required.
About Savara
Savara develops drugs for rare lung diseases and has not yet brought a product to market. Its lead candidate, molgramostim, is an inhaled version of a protein called GM-CSF, designed to treat autoimmune pulmonary alveolar proteinosis, a condition that affects the lungs' ability to clear surfactant buildup. This treatment is the company's most advanced program and is what it is primarily recognized for.
As a clinical-stage biopharmaceutical business, Savara does not generate revenue from approved products but instead focuses its resources on advancing molgramostim through testing, with the drug now in Phase III trials aimed at confirming its effectiveness and safety for patients with this rare respiratory disorder.
Savara runs its operations out of Austin, Texas. Its shares are listed on the NASDAQ under the ticker SVRA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- savarapharma.com
Savara GekkoIndex: the smart money zone
Savara’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.9, in the Accumulation zone, down 5.4 points over five sessions.
62.9Accumulation
Down 5.4 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 15 | +11.1% | +9.9% | ||
| Accumulation (current zone) | 280 | +0.7% | +1.1% | ||
| Neutral | 324 | −1.0% | +0.7% | ||
| Distribution | 61 | +3.0% | +2.8% | ||
| Selling | 2 | Too few readings yet | |||
Average SVRA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the SVRA price, zone by zone.Track SVRA in Gekko
Is Savara stock overvalued? Gekko Fair Value
Savara trades 34.0% below Gekko Fair Value of $7.33, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Savara shares are worth, recalculated every trading day.
$7.33
Gekko Fair Value, Oct 10, 2026
34.0% Undervalued
At the end of Aug 2026 the price was 40.8% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open SVRA in Gekko
Savara insider and Congress trading
No open-market insider purchases were filed for Savara, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SVRA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SVRA, plotted on the chart in Gekko.Open SVRA in Gekko
Buybacks
Savara has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $5K
- As a share of market cap
- 0.00%
- Trailing four quarters
- $5.06M
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold SVRA.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Savara earnings: next date and track record
Savara reports on Nov 11, 2026 (30 days away), and beat the EPS estimate in 0 of its last 8 reports.
Next earnings report
Nov 11, 2026
30 days away
- EPS estimate
- −$0.16
- Revenue estimate
- $500K
0 of 8reports beat the EPS estimate
±6.5%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | −$0.16 est −$0.14 | — est $2.00M | −0.5% |
| May 12, 2026 | −$0.15 est −$0.14 | — est $500K | +2.9% |
| Mar 13, 2026 | −$0.13 est −$0.12 | — | −1.7% |
| Nov 12, 2025 | −$0.14 est −$0.13 | — | −1.6% |
| Aug 13, 2025 | −$0.14 est −$0.12 | — | +16.7% |
| May 13, 2025 | −$0.12 est −$0.12 | — | −1.0% |
| Mar 27, 2025 | −$0.13 est −$0.11 | $272K | +7.8% |
| Nov 12, 2024 | −$0.11 est −$0.11 | — | −20.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Savara stock forecast and analyst price targets
Analysts’ average 12-month price target for Savara is $11.06, +128.5% from the last close, from 6 firms rating the stock in the last 90 days.
$11.06consensus 12-month target, +128.5% from the last close
Now $4.84Avg $11.06
Low $9High $16
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 7 | J.P. Morgan | $12 | +147.9% |
| Aug 26 | Piper Sandler | $16 | +230.6% |
| Aug 20 | Guggenheim | $11 | +127.3% |
| Aug 12 | LifeSci Capital | $10 | +106.6% |
| Aug 12 | H.C. Wainwright | $10 | +106.6% |
+1.1%average 20-day move after past Accumulation readings
+0.3%average move over the next 20 trading days in the last 5 years
±5.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Savara seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Savara averaged +0.3% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.2% | 2 of 5 |
| Next 10 trading days | −0.9% | 1 of 5 |
| Next 15 trading days | +1.9% | 2 of 5 |
| Next 20 trading days | +0.3% | 3 of 5 |
| Next 30 trading days | +6.7% | 3 of 5 |
For scale, SVRA’s typical 20-trading-day move in either direction is about 9.8%.
Savara market cap and key statistics
Savara’s market cap is $991.8M and revenue of $1K over the last twelve months.
Valuation
- Market cap
- $991.8M
- Forward P/E
- 0.4
- EPS, TTM
- −$0.58
- Gekko Fair Value
- $7.33
Trading
- Volume
- 1.31M
- Avg volume, 20 days
- 2.37M
- 52-week high
- $7.01
- 52-week low
- $3.35
- Shares outstanding
- 205.5M
Financials
- Revenue, TTM
- $1K
- Profit margin
- 0%
- Return on equity
- -105.5%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.20
- Typical daily move
- ±5.5%
- Typical 20-day move
- ±9.8%
Savara stock news this week
Coverage of Savara this week reads positive: 4 positive, 0 neutral and 0 negative headlines.
- Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026Business Wire, Oct 12
- Savara Has Lost 30% Since December: JPMorgan Sees 146% UpsideYahoo Finance, Oct 11
- JPMorgan starts Savara coverage with USD 12 target for Savara stockAD HOC NEWS, Oct 8
- JPMorgan Initiates Savara at Overweight With $12 Price TargetYahoo Finance, Oct 8
- Savara stock gets USD 12 JPMorgan target before FDA dateAD HOC NEWS, Oct 8
Savara peers
Savara’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Savara stock FAQ
What is Savara’s market cap?
Savara’s market cap is $991.8M at the Oct 12, 2026 close of $4.84, with 205.5M shares outstanding.
What is the Savara stock forecast?
The consensus analyst 12-month price target for Savara is $11.06, +128.5% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Savara stock overvalued or undervalued?
On Gekko’s estimate Savara is undervalued: the Oct 12, 2026 close of $4.84 is 34.0% below Gekko Fair Value of $7.33. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Savara report earnings next?
Savara is expected to report on Nov 11, 2026 (30 days away). Analysts expect earnings of −$0.16 per share on revenue of $500K. Savara beat the earnings estimate in 0 of its last 8 reports, moving 6.5% on average across the report.
What is Savara’s 52-week high and low?
Savara’s 52-week high is $7.01 and its 52-week low is $3.35; it closed at $4.84 on Oct 12, 2026, +41.5% over the past year.
Is Savara stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Savara the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.